Infusion Pumps Market- Outlook and Key Findings
- Global infusion pumps market is likely to surge at 5.4% CAGR from 2020-2030
- Chemotherapy/Oncology grade pumps to record heightened usage, attributed to rising cancer fatalities
- Surging geriatric population to induce accelerating growth trends across East & South Asian markets
- Portable smart wearable infusion pumps poised to witness increased adoption
- Collaborations and product launches characterize principal market expansion strategies of prominent vendors
High Incidence of Diabetes and Cancer to Push Forward Infusion Pumps Adoption
Infusion pumps are amongst the most extensively used devices to facilitate swift drug delivery to patients with chronic lifestyle diseases. Infusion pumps help facilitate medicine and nutrient delivery in fluid form within a patient’s body under controlled conditions. They have a widespread usage across hospitals, homes and nursing centers.
Over the years, the incidence of diabetes and cancers have recorded a phenomenal increase. According to the World Health Organization, 8.5% of people aged 18 years or older had diabetes in 2014. It was also the direct cause of over 1 million fatalities in 2016, while 9.6 million deaths occurred in 2018 due to cancer.
Based on the aforementioned statistics, the demand for reducing fatalities due to these diseases has prompted healthcare providers to adopt infusion pumps on a large scale. Infusion pumps also assist in reducing traumatic pain experienced by patients in post-surgical care. Vendors are introducing several enhancements to improve patient care outcomes.
Ambulatory Infusion Pumps to Emerge as a Lucrative Category
Ambulatory infusion pumps have proven highly instrumental in ensuring targeted drug and nutrient delivery among patients. Ambulatory infusion pumps are battery powered pumps which slowly and gradually deliver medicines such as antibiotics or chemotherapy drugs into the body. These pumps are popular as they do not interfere with the patient’s daily routine.
Ambulatory infusion pumps are capable of administering medication and other solutions intravenously, subcutaneously or epidurally, thus enhancing their functionality. These pumps are highly beneficial for patients requiring continuous infusions. These pumps provide parenteral nutrition to patients afflicted by gastrointestinal disorders and insulin to diabetic patients.
Based on this surging popularity, several vendors are emphasizing on accelerating ambulatory infusion pumps production and manufacturing. Some examples include Micrel’s Rhythmic Evolution Blue Chemotherapy Infusion Pump, MedRena’s UniFusion VP50 Pro Chemotherapy Infusion Pump and MedCaptain’s Sys-50 1 Channel Infusion Pump.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Smart Infusion Pumps will be the Future
Smart technologies have deeply penetrated all industrial verticals since the beginning of the 21st century. Over the years, impressive technological advancements have been witnessed in the infusion pumps market. Smart pumps have been instrumental in eliminating intravenous medication administration errors, particularly with respect to dosage for the most vulnerable patients.
Smart pumps use a database of medications, called drug libraries, and dose-error reduction rules software for providing information and decision support to nurses. The dosage specifications are generated by random parameters customized by the organization of a specific population. Such accuracies have helped deliver more efficient patient care for chronic ailments.
Presently, there are five prominent vendors involved in manufacturing smart infusion pumps. These include Fresenius Kabi, Becton Dickinson, Q-Core Medical, Micrel Medical Devices and Baxter International. These companies manufacture the Volumat MC Agilia, Sapphire Multi-Therapy, Alaris Infusion Products, Mini Rhythmic PN+ and the Evo IQ system respectively.
Regional Insights: Increasing Diabetic Population Pool Drives Growth in Europe and Asia
The global infusion pumps market is poised to experience maximum proliferation across the European market. According to W.H.O., over 60 million people suffer from type-1 and type-2 diabetes, accounting for nearly a quarter of the European population. Adoption of sedentary lifestyles is considered to be the key contributor in this respect.
Taking cognizance of this fact, regulatory authorities are modifying business laws to permit prominent infusion pump manufacturers to establish their production facilities across Europe. In 2019, Israeli infusion system specialist Q Core Medical opened a new unit in Marseille, France due to growing demand for smart pumps across healthcare settings.
The Asian market shows promising growth prospects for infusion pumps growth. This is majorly due to the prevalence of a high percentage of geriatric population, thus heightening the risk of diabetes. According to the Asian Diabetes Prevention Initiative, 3 out 5 diabetic patients reside in Asia.
Amongst all countries, China and India account for the largest share of the Asian diabetic population. By 2030, both countries will contribute nearly 500 million diabetics. As a result, the number of diabetic patient hospitalization is bound to increase, opening up opportunistic frontiers for infusion pumps vendors.
Government-Sanctioned Approvals Provide Breathing Space for Healthcare Providers
The coronavirus pandemic has ushered in an unprecedented era of uncertainty across the global healthcare industry. With the infection curve showing minimal signs of flattening, healthcare providers are racing against time to provide the best quality care to infected patients.
The pandemic is anticipated to have a moderate impact on the global infusion pumps market. In the initial months of the pandemic’s onset, a slump in the demand-supply equation was observed. This was in response to the imposition of lockdowns and social distancing protocols. Eventually, a resurgence was recorded.
In recent months, regulatory authorities such as the U.S Food and Drug Administration (FDA) issued emergency use authorization to increase the availability of infusion pumps and related accessories. Infusion pumps have been pivotal in administering vital medicines and parenteral nutrition to patients admitted for chronic ailments.
Taking note of this development, B. Braun Medical Inc. has increased its supply of Perfusor Space Syringe Infusion Pump, the Infusomat Space Volumetric Infusion Pump and the Outlook ES Pump Systems. These are to be used in ensuring tracheal delivery of nebulized medications to treat infected patients.
As hospitals reach a saturation point, governments are providing flexibility to infusion pump manufacturers to address supply shortages by permitting them to resume operations. This is slated to sustain the infusion pumps market demand in the short-term forecast.
Home Care Infusion Pumps to Record Impressive Upsurge, Attributed to Favorable Reimbursement Coverage
In recent months, home care infusion pumps usage has recorded a substantial upsurge, particularly across the United States. This is largely due to the handsome reimbursement coverage offered by U.S Medicare on some components of home infusion. Part B of the Medicare program elaborates on the incentives offered for home medical care.
The home care segment includes reimbursement coverages for services such as nursing care, occupational therapy, physical therapy, medical social services and injectable drugs for women. The intermittent care segment includes infusion procedures. Some infusion pumps which can be used at home include PCA infusion pumps, insulin pumps and elastomeric infusion pumps.
Collaborations, Product Launches & Acquisitions
Prominent players in the infusion pumps landscape include Fresenius Kabi AG, Terumo Corporation, Medtronic Plc, Baxter International Plc., Smith Medical, MOOG Inc., Johnson & Johnson Services Inc., ICU Medical Inc. and Becton Dickinson & Company among others.
Product launches, expansions, collaborations and other inorganic strategies are being pursued by the aforementioned players. In 2019, Terumo Corporation announced the launch of its TERUFUSION Infusion Pump Type LM Series which utilize smart cutting-edge IT solutions to deliver optimal management and prevents inadvertent excess infusion of drugs into the patient.
In 2010, Hospira Inc. partnered with Smith Medical to market and promote various infusion pumps. The companies collaborated in order to co-promote Hospira’s Symbiq and Plum A+ general infusion pumps along with its Hospira MedNet safety software. The venture also promoted Smith Medical’s Medfusion syringe pumps with the PharmGuard Medication Safety Software.
In 2015, the company was acquired by Pfizer as a part of the latter’s objective to create a leading global established pharmaceutical business. While the primary goal was to acquire the biosimilar portfolio, the acquisition also transferred ownership of infusion pumps to the latter.
In 2017, Baxter International developed and launched its SIGMA SPECTRUM Infusion System. The system offers unique generation 2 safety features capable of averting dosage errors and streamlining patient treatment. The system offers single step titration error prevention, secondary infusion container check and inspection of flow at the beginning of the infusion.
In 2019, the U.S FDA authorized the commercial-grade marketing of the Tandem Diabetes Care Slim X2 Insulin Pump with interoperable technology to deliver insulin under the skin for adults and children with diabetes.
In May 2019, ICU Medical Inc. successfully integrated the MedNet Software platform with the Vocera platform. This integration enables hospitals to transmit and selectively filter alarms from IV smart infusion pumps directly to clinicians’ hands-free Vocera Smartbadges and other mobile devices. This helps reduce response time and provide clinical awareness.
In February 2011, Becton Dickinson & Company released the BodyGuard 121 Twins Infusion System. The pump is designed to manage both on-the-go and bedside patient regimens. The device simplifies management of multiple infusion protocols with a single device designated to save space. The device helps streamline workflow and increases safety and flexibility.
- Syringe Pumps
- Ambulatory Pumps
- Volumetric Pumps (Peristaltic and Cassette/Piston)
- Implantable Pumps
- Insulin Pumps
- Enteral Pumps
- PCA Pumps
- Pump Accessories
- Ambulatory Surgical Centers
- North America
- Latin America
- Middle East & Africa (MEA)
- East Asia
- South Asia